Crossmark

Epidemiology of sarcopenia and insight into possible therapeutic targets

Crossref DOI link: https://doi.org/10.1038/nrrheum.2017.60

Published Online: 2017-05-04

Published Print: 2017-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dennison, Elaine M.

Sayer, Avan A.

Cooper, Cyrus
License Information

Text and Data Mining valid from 2017-05-04
More Information

Article History

First Online: 4 May 2017

Competing interests

: C.C. declares that he has received consultancy fees and honoraria from Alliance for Better Bone Health, Amgen, GSK, Lilly, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. E.M.D. declares that she has received speaker's fees from Lilly. A.S. declares no competing interests.